Dyne Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Dyne Therapeutics

12/11/2024 15:27

* Dyne Therapeutics Inc  DYN.OQ  reported a quarterly
adjusted
loss of 96 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -99 cents.  The mean expectation of ten analysts
for the quarter was for a loss of 71 cents per share. Wall
Street expected results to range from -80 cents to -61 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Dyne Therapeutics Inc's reported EPS for the quarter was a
loss
of 96 cents​.
    * The company reported a quarterly loss of $97.13 million.
    * Dyne Therapeutics Inc shares had fallen by 21.7% this
quarter and gained 111.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 1.1%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Dyne Therapeutics
Inc is 52.50 
This summary was machine generated from LSEG data November 12 at
03:27 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.71          -0.96          Missed
 Jun. 30 2024      -0.72          -0.70          Beat
 Mar. 31 2024      -0.80          -0.81          Missed
 Dec. 31 2023      -0.92          -1.09          Missed